VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ The patients signed the written informed consent   │ The patients signed the written informed consent   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patients present with operable unilateral      │ The patients present with operable unilateral      │     100 │
│ invasive breast cancers without distant            │ invasive breast cancers without distant            │         │
│ metastasis(stage I, II, and III)                   │ metastasis(stage I, II, and III)                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patients have no history of neoadjuvant        │ The patients have no history of neoadjuvant        │     100 │
│ hormone therapy                                    │ hormone therapy                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patients have normal cardiac functions by      │ The patients have normal cardiac functions by      │     100 │
│ echocardiography                                   │ echocardiography                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patients are non-pregnant, and disposed to     │ The patients are non-pregnant, and disposed to     │     100 │
│ practice contraception during the whole trial      │ practice contraception during the whole trial      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patients underwent neoadjuvant chemotherapy    │ The patients underwent neoadjuvant chemotherapy    │     100 │
│ plus surgery or directly modified radical          │ plus surgery or directly modified radical          │         │
│ mastectomy or breast-conserving surgery (plus      │ mastectomy or breast-conserving surgery (plus      │         │
│ sentinel lymph node biopsy or axillary lymph node  │ sentinel lymph node biopsy or axillary lymph node  │         │
│ dissection) after diagnosis of breast cancer       │ dissection) after diagnosis of breast cancer       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patients underwent chemotherapy, radiation     │ The patients underwent chemotherapy, radiation     │     100 │
│ therapy or targeted therapy(herceptin) after       │ therapy or targeted therapy(herceptin) after       │         │
│ surgery according to the 2013 NCCN guideline       │ surgery according to the 2013 NCCN guideline       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The results of patients' blood tests are as        │ The results of patients' blood tests are as        │     100 │
│ follows                                            │ follows                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patients have other cancers at the same time   │ The patients have other cancers at the same time   │     100 │
│ or have the history of other cancers except        │ or have the history of other cancers except        │         │
│ controlled skin basal cell carcinoma or skin       │ controlled skin basal cell carcinoma or skin       │         │
│ squamous cell carcinoma or carcinoma in situ of    │ squamous cell carcinoma or carcinoma in situ of    │         │
│ cervix uterus                                      │ cervix uterus                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patients have active infections that were not  │ The patients have active infections that were not  │     100 │
│ suitable for chemotherapy                          │ suitable for chemotherapy                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patients have severe non-cancerous diseases    │ The patients have severe non-cancerous diseases    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patients have history of neoadjuvant hormone   │ The patients have history of neoadjuvant hormone   │     100 │
│ therapy                                            │ therapy                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patients have bilateral breast cancers or DCIS │ The patients have bilateral breast cancers or DCIS │     100 │
│ or metastatic breast cancers                       │ or metastatic breast cancers                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patients are undergoing current administration │ The patients are undergoing current administration │     100 │
│ of anti-cancer therapies, or are attending other   │ of anti-cancer therapies, or are attending other   │         │
│ clinical trials                                    │ clinical trials                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patients are pregnant or lactational, or they  │ The patients are pregnant or lactational, or they  │     100 │
│ refuse to practice contraception during the whole  │ refuse to practice contraception during the whole  │         │
│ trial                                              │ trial                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patients are in some special conditions that   │ The patients are in some special conditions that   │     100 │
│ they can't understand the written informed         │ they can't understand the written informed         │         │
│ consent, such as they are demented or hawkish      │ consent, such as they are demented or hawkish      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patients have allergic history or              │ The patients have allergic history or              │     100 │
│ contraindication of tamoxifen                      │ contraindication of tamoxifen                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female patient who is ≥ 18yrs, and ≤ 70yrs         │ Female patient who is = 18yrs, and = 65yrs         │      90 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patients' ECOG scores are ≤0-2                 │ The patients' ECOG scores are =0-2                 │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The breast tumor's positive ER/PR rate is \<1%,    │ The breast tumor's positive ER/PR rate is <1%, and │      98 │
│ and positive ER-beta1 rate is ≥10% by IHC          │ positive ER-beta1 rate is =10% by IHC              │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════╤══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                              │ CHIA Criteria                                    │   Score │
╞════════════════════════════════════════════════╪══════════════════════════════════════════════════╪═════════╡
│ Must be FEMALE                                 │ The results of patients' blood tests are as      │      22 │
│                                                │ follows                                          │         │
├────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Hb≥90g/L; WBC≥4.0×109/L; Plt≥100×109/L;        │ The patients have other cancers at the same time │      32 │
│ Neutrophils≥1.5×109/L; ALT and AST ≤ triple of │ or have the history of other cancers except      │         │
│ normal upper limit; TBIL ≤ 1.5 times of normal │ controlled skin basal cell carcinoma or skin     │         │
│ upper limit; Creatinine ≤ 1.25 times of normal │ squamous cell carcinoma or carcinoma in situ of  │         │
│ upper limit                                    │ cervix uterus                                    │         │
├────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years              │ The patients have normal cardiac functions by    │      38 │
│                                                │ echocardiography                                 │         │
├────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 70 Years              │ The patients have normal cardiac functions by    │      38 │
│                                                │ echocardiography                                 │         │
╘════════════════════════════════════════════════╧══════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 93
Average Levenshtein Ratio of individual lines: 88.125
OverAll Ratio: 90.5625
